EF1AKMT4: A Non-Code RNA Molecule Regulating MRNA Translation and Lysine Methylation

Target Name: EEF1AKMT4

NCBI ID: G110599564

EEF1AKMT4

Other Name(s): Eukaryotic translation elongation factor 1 alpha lysine specific methyltransferase 4 | EFMT4_HUMAN | EEF1A lysine methyltransferase 4 | eukaryotic translation elongation factor 1 alpha lysine specific methyltransferase 4

EF1AKMT4: A Non-Code RNA Molecule Regulating MRNA Translation and Lysine Methylation

Eukaryotic Translation Elongation Factor 1 Alpha Lysine Specific Methyltransferase 4 (EF1AKMT4) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. It is a key component of the eukaryotic translation machinery, which is responsible for the translation of mRNAs from the DNA to protein.

One of the unique features of EF1AKMT4 is its ability to modify the alpha-methylation state of specific lysine residues on mRNAs. This process is known as methylation, and it plays a crucial role in the regulation of various cellular processes, including cell growth, differentiation , and inflammation.

EF1AKMT4 is highly conserved across different species, which suggests that it is an important gene that is involved in the basic principles of gene function. It is expressed in a variety of tissues and cells, including muscle, liver, and brain, and it has been implicated in the development and progression of various diseases, including cancer.

Despite its importance, there is limited research on EF1AKMT4 as a drug target or biomarker. This is because the function of EF1AKMT4 is not well understood, and there are few known diseases that are directly related to its dysfunction.

One potential drug target for EF1AKMT4 is the regulation of its expression. By inhibiting the activity of EF1AKMT4, it may be possible to reduce the levels of mRNAs that are translated from DNA and to stabilize the alpha-methylation state of lysine residues on those mRNAs. This could have potential therapeutic applications in diseases where the translation of mRNAs is either excessive or deficient.

Another potential drug target for EF1AKMT4 is its role in the regulation of cellular processes that are affected by the alpha-methylation state of lysine residues. For example, EF1AKMT4 has been shown to be involved in the regulation of cell adhesion, which is a critical process that is involved in the development and maintenance of tissues and organs.

In addition to its potential drug targets, EF1AKMT4 may also be a biomarker for various diseases. For example, high levels of EF1AKMT4 have been observed in various types of cancer, and it has been suggested that it may be a potential biomarker for these diseases.

Overall, EF1AKMT4 is a fascinating molecule, and its role in the regulation of gene expression and cellular processes is not yet well understood. Further research is needed to fully understand its function and potential as a drug target or biomarker.

Protein Name: EEF1A Lysine Methyltransferase 4

Functions: Protein-lysine methyltransferase that efficiently catalyzes three successive methylations on 'Lys-36' in eukaryotic translation elongation factor 1 alpha (EEF1A1 or EEF1A2)

The "EEF1AKMT4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1AKMT4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets